Robert Davis, PhD

Results From a 12-Month Open-Label Safety Study of Lumateperone (ITI-007) in Patients With Stable Symptoms of Schizophrenia

Introduction: Lumateperone (ITI-007) is in development for the treatment of schizophrenia and bipolar depression. Lumateperone has a unique mechanism of action that simultaneously modulat...

Jelena Saillard , MS, MBA;

Christoph U. Correll , MD;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Sharon Mates , PhD;

Kimberly Vanover , PhD;

11/22/2019

Lumateperone in the Treatment of Schizophrenia: Efficacy in Demographic and Clinical Subgroups

Introduction: Patients with schizophrenia are a heterogenous population and understanding which factors may influence antipsychotic efficacy is important in improving outcomes. Lumatepero...

Sharon Mates , PhD;

Kimberly Vanover , PhD;

Ian D'Souza , PhD;

Roger McIntyre , MD, FRCPC;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

11/22/2019

Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-label Safety Switching Study

Background: Lumateperone is a first-in-class agent in development for schizophrenia that acts synergistically through serotonergic, dopaminergic and glutamatergic systems.

Kimberly Vanover , PhD;

Jelena Saillard , MS, MBA;

Steven Glass , MD;

Susan Kazaouer , MD;

Michal Weingart , PhD;

Robert Davis , PhD;

Andrew Satlin , MD;

Sharon Mates , PhD;

03/01/2019

News

Study: Fewer Paramedics Means More Lives Saved

05/22/2006

Robert Davis , PhD;

Cities that deploy fewer paramedics -- who in turn treat more victims of sudden cardiac arrest -- save more lives, according to a new study.

Cities that deploy fewer...

05/22/2006

EMSWorld

News

Traumas Create Unwitting Test Subjects

06/13/2006

Robert Davis , PhD;

With waived-consent studies becoming more prevalent, critics question whether the public understands how they work and whether test subjects get adequate protection.

With waived-consent studies...

06/13/2006

EMSWorld

News

D.C. EMS Chief Apologizes for Man`s Death

06/19/2006

Robert Davis , PhD;

Chief Adrian Thompson told the family of a New York Times journalist that he is sorry for the poor EMS response.

Chief Adrian Thompson told the...

06/19/2006

EMSWorld

Somnolence and Sedation with Lumateperone Treatment: A Comparison of Morning and Evening Administration

Background: Somnolence and sedation are common treatment-emergent adverse events (TEAEs) reported with current antipsychotics. Lumateperone (lumateperone tosylate, ITI-007), a mechanistic...

Sharon Mates , PhD;

Andrew J. Cutler , MD;

William Rowe , MSN, RN, ACNP, BC;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Jason Huo , PhD;

10/08/2020

News

Induced Hypothermia Gets Cold Shoulder in Most U.S. Cities

12/10/2006

Robert Davis , PhD;

This hypothermia treatment is standard care in a few cities, but it's unavailable in most, illuminating a sharp medical disparity across the nation.

This hypothermia treatment is...

12/10/2006

EMSWorld

Efficacy and Safety of Lumateperone (ITI-007) in the Treatment of Depressive Episodes Associated With Bipolar I and II Disorders

Background: Treatments for bipolar depression are limited. Lumateperone (lumateperone tosylate, ITI-007), a mechanistically novel antipsychotic that simultaneously modulates serotonin, do...

Joseph Calabrese , MD;

Suresh Durgam , MD;

Robert Davis , PhD;

Andrew Satlin , MD;

Jason Huo , PhD;

Sharon Mates , PhD;

Ian D'Souza , PhD;

Susan Kozauer , MD;

10/08/2020

News

FDA Gives Green Light to Cyanide Treatment

12/25/2006